JP2025036561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025036561A5 JP2025036561A5 JP2024228911A JP2024228911A JP2025036561A5 JP 2025036561 A5 JP2025036561 A5 JP 2025036561A5 JP 2024228911 A JP2024228911 A JP 2024228911A JP 2024228911 A JP2024228911 A JP 2024228911A JP 2025036561 A5 JP2025036561 A5 JP 2025036561A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 150
- 235000001014 amino acid Nutrition 0.000 claims 69
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 4
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000006240 deamidation Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015187488 | 2015-09-24 | ||
| JP2015187488 | 2015-09-24 | ||
| JP2021075739A JP7137657B2 (ja) | 2015-09-24 | 2021-04-28 | 抗ｇａｒｐ抗体 |
| JP2022140119A JP2022169801A (ja) | 2015-09-24 | 2022-09-02 | 抗ｇａｒｐ抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140119A Division JP2022169801A (ja) | 2015-09-24 | 2022-09-02 | 抗ｇａｒｐ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025036561A JP2025036561A (ja) | 2025-03-14 |
| JP2025036561A5 true JP2025036561A5 (enExample) | 2025-04-17 |
Family
ID=58386752
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540925A Active JP6878283B2 (ja) | 2015-09-24 | 2016-09-23 | 抗ｇａｒｐ抗体 |
| JP2020164126A Active JP6868739B2 (ja) | 2015-09-24 | 2020-09-29 | 抗ｇａｒｐ抗体 |
| JP2021075739A Active JP7137657B2 (ja) | 2015-09-24 | 2021-04-28 | 抗ｇａｒｐ抗体 |
| JP2022140119A Pending JP2022169801A (ja) | 2015-09-24 | 2022-09-02 | 抗ｇａｒｐ抗体 |
| JP2024228911A Pending JP2025036561A (ja) | 2015-09-24 | 2024-12-25 | 抗ｇａｒｐ抗体 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540925A Active JP6878283B2 (ja) | 2015-09-24 | 2016-09-23 | 抗ｇａｒｐ抗体 |
| JP2020164126A Active JP6868739B2 (ja) | 2015-09-24 | 2020-09-29 | 抗ｇａｒｐ抗体 |
| JP2021075739A Active JP7137657B2 (ja) | 2015-09-24 | 2021-04-28 | 抗ｇａｒｐ抗体 |
| JP2022140119A Pending JP2022169801A (ja) | 2015-09-24 | 2022-09-02 | 抗ｇａｒｐ抗体 |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US11046780B2 (enExample) |
| EP (3) | EP4349997A3 (enExample) |
| JP (5) | JP6878283B2 (enExample) |
| KR (2) | KR102776730B1 (enExample) |
| CN (3) | CN110922481A (enExample) |
| AU (3) | AU2016325858B2 (enExample) |
| BR (1) | BR112018005777A2 (enExample) |
| CA (1) | CA2999819A1 (enExample) |
| CO (1) | CO2018003542A2 (enExample) |
| DK (1) | DK3354729T5 (enExample) |
| ES (1) | ES2978126T3 (enExample) |
| FI (1) | FI3354729T3 (enExample) |
| HR (1) | HRP20240495T1 (enExample) |
| HU (1) | HUE066594T2 (enExample) |
| IL (3) | IL288784B2 (enExample) |
| LT (1) | LT3354729T (enExample) |
| MX (2) | MX2018003594A (enExample) |
| MY (1) | MY194586A (enExample) |
| PH (1) | PH12018500642A1 (enExample) |
| PL (1) | PL3354729T3 (enExample) |
| PT (1) | PT3354729T (enExample) |
| RS (1) | RS65415B1 (enExample) |
| RU (2) | RU2022108079A (enExample) |
| SG (2) | SG11201802352VA (enExample) |
| SI (1) | SI3354729T1 (enExample) |
| SM (1) | SMT202400160T1 (enExample) |
| TW (2) | TWI751979B (enExample) |
| WO (1) | WO2017051888A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658666B (zh) | 2013-08-01 | 2021-07-27 | 鲁汶大学 | 抗garp蛋白及其用途 |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| CN110922481A (zh) | 2015-09-24 | 2020-03-27 | 第一三共株式会社 | 抗garp抗体 |
| CN109195990A (zh) * | 2016-03-30 | 2019-01-11 | Musc研究发展基金会 | 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES |
| CA3099900A1 (en) * | 2018-05-31 | 2019-12-05 | Daiichi Sankyo Company, Limited | Anti-human tlr7 antibody |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| BR112022007632A2 (pt) * | 2019-10-25 | 2022-07-12 | Daiichi Sankyo Co Ltd | Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer |
| US20230192867A1 (en) * | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| EP4255473A4 (en) * | 2020-12-02 | 2025-02-19 | Shanghai Henlius Biotech, Inc. | Anti-garp/tgfbeta antibodies and methods of use |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| CN117425500A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗dll3抗体-药物缀合物 |
| EP4277664A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| CN1333274A (zh) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸 |
| MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
| CA2465314C (en) | 2001-11-01 | 2013-12-10 | The Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| DK1583830T3 (da) | 2003-01-07 | 2007-01-15 | Symphogen As | Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner |
| WO2006089678A2 (en) | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| WO2006103639A2 (en) | 2005-03-31 | 2006-10-05 | Case Western Reserve University | Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals |
| US20110086367A1 (en) | 2006-04-03 | 2011-04-14 | Medizinische Hochschule Hannover | Pharmaceuticals for influencing the reaction of the human immune system |
| AR064610A1 (es) | 2006-12-22 | 2009-04-15 | Schering Corp | Anticuerpos contra el cd200r |
| EP2235181A1 (en) | 2008-01-11 | 2010-10-06 | MorphoSys AG | Display vectors and methods and uses thereof |
| US8114968B2 (en) | 2008-03-03 | 2012-02-14 | Dyax Corp. | Metalloproteinase-12 specific monoclonal antibody |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20110287036A1 (en) | 2008-11-17 | 2011-11-24 | Riken | Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound |
| TWI480050B (zh) | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| RU2571224C2 (ru) | 2009-05-11 | 2015-12-20 | УЗ ФАРМА ГмбХ | Гуманизированные антитела против axl |
| TWI688395B (zh) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
| HRP20160584T1 (hr) | 2010-10-29 | 2016-06-17 | Daiichi Sankyo Company, Limited | Novo anti-dr5 antitijelo |
| US8440797B2 (en) | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| PH12013502201A1 (en) * | 2011-04-25 | 2014-01-13 | Daiichi Sankyo Co Ltd | Anti-b7-h3 antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2013147212A1 (ja) | 2012-03-30 | 2013-10-03 | 第一三共株式会社 | 新規抗Ｓｉｇｌｅｃ－１５抗体 |
| TWI669313B (zh) | 2012-04-09 | 2019-08-21 | 第一三共股份有限公司 | 抗ＦＧＦＲ２抗體及其製造方法、及檢測或測定人類ＦＧＦＲ２ＩＩＩｂ之方法 |
| WO2013160879A1 (en) | 2012-04-27 | 2013-10-31 | Daiichi Sankyo Company, Limited | Anti-robo4-antibody |
| JP2014141434A (ja) | 2013-01-24 | 2014-08-07 | Daiichi Sankyo Co Ltd | 抗ｒｏｂｏ４抗体 |
| BR112014032276A2 (pt) * | 2012-06-22 | 2017-11-28 | King S College London | construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios |
| ES2782248T3 (es) * | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| SG11201503271XA (en) * | 2012-11-06 | 2015-05-28 | Scholar Rock Inc | Compositions and methods for modulating cell signaling |
| CN105658666B (zh) | 2013-08-01 | 2021-07-27 | 鲁汶大学 | 抗garp蛋白及其用途 |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| WO2016125017A1 (en) | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| CN110922481A (zh) * | 2015-09-24 | 2020-03-27 | 第一三共株式会社 | 抗garp抗体 |
| CN109195990A (zh) * | 2016-03-30 | 2019-01-11 | Musc研究发展基金会 | 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法 |
-
2016
- 2016-09-23 CN CN201911407390.3A patent/CN110922481A/zh active Pending
- 2016-09-23 US US15/761,045 patent/US11046780B2/en active Active
- 2016-09-23 PL PL16848676.9T patent/PL3354729T3/pl unknown
- 2016-09-23 AU AU2016325858A patent/AU2016325858B2/en active Active
- 2016-09-23 EP EP24157462.3A patent/EP4349997A3/en active Pending
- 2016-09-23 PT PT168486769T patent/PT3354729T/pt unknown
- 2016-09-23 RU RU2022108079A patent/RU2022108079A/ru unknown
- 2016-09-23 WO PCT/JP2016/078067 patent/WO2017051888A1/ja not_active Ceased
- 2016-09-23 CN CN202211442176.3A patent/CN115869398B/zh active Active
- 2016-09-23 TW TW105130782A patent/TWI751979B/zh active
- 2016-09-23 CN CN201680056149.9A patent/CN108026521B/zh active Active
- 2016-09-23 ES ES16848676T patent/ES2978126T3/es active Active
- 2016-09-23 RU RU2018114904A patent/RU2769379C2/ru active
- 2016-09-23 KR KR1020187008255A patent/KR102776730B1/ko active Active
- 2016-09-23 SM SM20240160T patent/SMT202400160T1/it unknown
- 2016-09-23 KR KR1020257006887A patent/KR20250037587A/ko active Pending
- 2016-09-23 SG SG11201802352VA patent/SG11201802352VA/en unknown
- 2016-09-23 IL IL288784A patent/IL288784B2/en unknown
- 2016-09-23 FI FIEP16848676.9T patent/FI3354729T3/fi active
- 2016-09-23 MY MYPI2018000433A patent/MY194586A/en unknown
- 2016-09-23 DK DK16848676.9T patent/DK3354729T5/da active
- 2016-09-23 TW TW110146254A patent/TWI836305B/zh active
- 2016-09-23 EP EP19218146.9A patent/EP3660051A1/en active Pending
- 2016-09-23 IL IL258322A patent/IL258322B2/en unknown
- 2016-09-23 HR HRP20240495TT patent/HRP20240495T1/hr unknown
- 2016-09-23 BR BR112018005777-0A patent/BR112018005777A2/pt active Search and Examination
- 2016-09-23 HU HUE16848676A patent/HUE066594T2/hu unknown
- 2016-09-23 LT LTEPPCT/JP2016/078067T patent/LT3354729T/lt unknown
- 2016-09-23 IL IL302932A patent/IL302932A/en unknown
- 2016-09-23 RS RS20240428A patent/RS65415B1/sr unknown
- 2016-09-23 CA CA2999819A patent/CA2999819A1/en active Pending
- 2016-09-23 SI SI201631810T patent/SI3354729T1/sl unknown
- 2016-09-23 JP JP2017540925A patent/JP6878283B2/ja active Active
- 2016-09-23 EP EP16848676.9A patent/EP3354729B1/en active Active
- 2016-09-23 MX MX2018003594A patent/MX2018003594A/es unknown
- 2016-09-23 SG SG10201912570UA patent/SG10201912570UA/en unknown
-
2018
- 2018-03-22 PH PH12018500642A patent/PH12018500642A1/en unknown
- 2018-03-22 MX MX2023003470A patent/MX2023003470A/es unknown
- 2018-04-03 CO CONC2018/0003542A patent/CO2018003542A2/es unknown
- 2018-07-24 US US16/044,196 patent/US10550198B2/en active Active
-
2020
- 2020-02-06 AU AU2020200866A patent/AU2020200866B2/en active Active
- 2020-09-29 JP JP2020164126A patent/JP6868739B2/ja active Active
-
2021
- 2021-04-28 JP JP2021075739A patent/JP7137657B2/ja active Active
- 2021-06-28 US US17/361,137 patent/US12006372B2/en active Active
-
2022
- 2022-09-02 JP JP2022140119A patent/JP2022169801A/ja active Pending
- 2022-09-14 AU AU2022231706A patent/AU2022231706B2/en active Active
-
2024
- 2024-04-30 US US18/650,725 patent/US20240360245A1/en active Pending
- 2024-12-25 JP JP2024228911A patent/JP2025036561A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025036561A5 (enExample) | ||
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| JP5734988B2 (ja) | Ｒｓｖ特異的結合分子 | |
| PH12021500002A1 (en) | ANTIBODY-SIRPa ANTIBODY | |
| JP2023071956A5 (enExample) | ||
| JP2023129543A5 (enExample) | ||
| JP2022075818A5 (enExample) | ||
| JP2023015301A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2021106617A5 (enExample) | ||
| JP2011504501A5 (enExample) | ||
| JP2020506900A5 (enExample) | ||
| RU2009136677A (ru) | Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2012504955A5 (enExample) | ||
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| JP2024016201A5 (enExample) | ||
| CN114641495B (zh) | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 | |
| JPWO2020059847A5 (enExample) | ||
| JP2024109911A5 (enExample) | ||
| JP2018514193A5 (enExample) | ||
| JP2015515490A5 (enExample) | ||
| JP2021501579A5 (enExample) | ||
| JP2023510864A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用 |